Table 2.
Clinicopathologic characteristics compared by previous docetaxel chemotherapy
| Characteristics | Docetaxel-naïve cohort (n=103) | Docetaxel-resistant cohort (n=43) | P |
|---|---|---|---|
| Age (year), mean (s.d.) | 72.5 (7.6) | 73.6 (7.4) | 0.423 |
| PSA (ng ml−1), median (IQR) | 73.9 (66.2–77.7) | 72.9 (68.3–78.7) | 0.668 |
| Hemoglobin (g l−1), mean (s.d.) | 120.2 (20.9) | 114.9 (22.7) | 0.178 |
| ALP (U l−1), mean (s.d.) | 142.2 (132.0) | 124.9 (98.7) | 0.444 |
| LDH (U l−1), mean (s.d.) | 214.2 (91.1) | 258.3 (133.4) | 0.056 |
| ALB (g l−1), mean (s.d.) | 40.3 (11.6) | 35.3 (11.9) | 0.039* |
| Duration of previous hormonal therapy (month), median (IQR) | 14.0 (6.0–36.8) | 17.0 (10.5–51.5) | 0.129 |
| ECOG performance status, n (%) | |||
| 0–1 | 91 (88.3) | 40 (93.0) | 0.554 |
| ≥2 | 12 (11.7) | 3 (7.0) | |
| Stage at initial diagnosis, n (%) | |||
| M0 | 10 (9.7) | 3 (7.0) | 0.756 |
| M1 | 93 (90.3) | 40 (93.0) | |
| Gleason score of primary lesion, n (%) | |||
| 5–7 | 28 (27.2) | 11 (25.6) | 0.842 |
| 8–10 | 75 (72.8) | 32 (74.4) | |
| Extent of disease, n (%) | |||
| 0–5 metastatic sites | 66 (64.1) | 25 (58.1) | 0.500 |
| >5 metastatic sites | 37 (35.9) | 18 (41.9) | |
| Visceral metastases, n (%) | |||
| Yes | 12 (11.7) | 3 (7.0) | 0.554 |
| No | 91 (88.3) | 40 (93.0) | |
PSA: prostate-specific antigen; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; ALB: albumin; ECOG: Eastern Cooperative Oncology Group; s.d.: standard deviation; IQR: interquartile range. *Statistically significant